Topical Treatment For Primary Axillary Hyperhidrosis Therapeutics
1. Sofdra patent expiration
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8147809 | BOTANIX SB | Soft anticholinergic esters |
Mar, 2027
(1 year, 2 months from now) | |
| US11566000 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| US11584715 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357609 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US12398102 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US12156865 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(11 years from now) | |
| US11084788 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11052067 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11034652 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11026919 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10961191 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10959983 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US9220707 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US8628759 | BOTANIX SB | Soft anticholinergic esters |
Nov, 2026
(10 months from now) | |
| US10952990 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10947192 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10383846 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9492429 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9895350 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
